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Down Syndrome (DS) is the most common chromosomal disorder. Although DS individuals are mostly perceived as characterized
by some distinct physical features, cognitive disabilities, and cardiac defects, they also show important dysregulations of immune
functions. While critical information is available for adults with DS, little literature is available on the neuroinflammation in
prepubertal DS children. We aimed to evaluate in prepubertal DS children the serum levels of nerve growth factor (NGF) and
brain-derived neurotrophic factor (BDNF), oxidative stress as free oxygen radicals defense (FORD), free oxygen radicals test
(FORT), and cytokines playing key roles in neuroinflammation and oxidative processes as TNF-α, TGF-β, MCP-1, IL-1α, IL-2,
IL-6, IL-10, and IL-12. No differences were found in NGF between DS children and controls. However, BDNF was higher in DS
subjects compared to controls. We also did not reveal changes in FORD and FORT. Quite interestingly, the serum of DS
children disclosed a marked decrease in all analyzed cytokines with evident differences in serum cytokine presence between
male and female DS children. In conclusion, the present study evidences in DS prepubertal children a disruption in the
neurotrophins and immune system pathways.
1. Introduction
Down Syndrome (DS), also known as trisomy 21 for the
presence of an extra copy of the chromosome 21 that leads
to a wide spectrum of cognitive and physical symptoms, is
one of the most common chromosomal disorders occurring
in about 1 in 800 newborns worldwide [1]. The extra chro-
mosome disrupts the normal course of physical development
and results in mild to moderate intellectual disabilities. DS
people are also characterized by some distinct physical fea-
tures, such as a flat-looking face, and by a high risk for a
number of other health conditions including infections,
alteration of the immune system, thyroid, pulmonary, skel-
etal, skin, hearing and vision issues, diabetes, sleep apnea,
seizures, early menopause, and congenital heart defects [2].
There are a number of studies showing changes in several
aspects of the humoral and cellular immune system associ-
ated with DS, including functional impairments of B and
T lymphocytes and natural killer cells and dysfunctions
in phagocytosis and chemotaxis of polymorphonuclear
leukocytes [3–5].
Individuals with DS exhibit disturbances in thymic devel-
opment [4] and also show, besides low B-lymphocyte num-
bers, a dysregulated immunoglobulin pattern [6]. There are
Hindawi
Journal of Immunology Research
Volume 2020, Article ID 6937154, 10 pages
https://doi.org/10.1155/2020/6937154
also a number of reports showing increased levels of cyto-
kines leading to a proinflammatory profile, such as Inter-
feron-γ (IFN-γ), Interleukin-6 (IL-6), and Tumor Necrosis
Factor-alpha (TNF-α), in individuals with DS [7–9].
It is known that chromosome 21 of humans and chro-
mosome 16 of mice carry genes that are involved in the
function of the IFN family of cytokines and receptors [5]
and that overexpression of chromosome 21-gene products
causes changes in inflammatory cytokines in the blood [10],
as TNF-α and IFN-γ that have several biological effects in
the body, including important regulatory roles in immune
responses. It has been hypothesized that abnormal produc-
tion of proinflammatory cytokines might participate in the
neuropathological changes associated with DS, such as
Alzheimer’s-like mental retardation [8, 11].
Studies on inflammatory and autoimmune diseases,
which are characterized by abnormal activation of immune
cells and an increased production of cytokines, have revealed
a localized increase in NGF at the sites of inflammation or in
the blood [12]. NGF plays an essential role in the differentia-
tion, survival, and functions of neuronal cells in the central
and peripheral nervous system [13, 14]. Moreover, NGF
has a role outside the nervous system and in the cardiovascular
and immune systems [15–17]. NGF expression and functional
activities have now been well demonstrated for human baso-
phils, monocyte/macrophages, and T- and B-lymphocytes
[18, 19]. In this context, a number of studies have shown that
the plasma and/or serum NGF levels are disrupted in several
autoimmune, inflammatory, and fibrotic disorders [20–23].
Brain-derived neurotrophic factor (BDNF) is another growth
factor which plays a central role in the survival and differ-
entiation of neurons [24, 25], but apart from nervous system
disorders, several reports documented an association between
plasma BDNF and systemic or peripheral inflammatory con-
ditions [26]. It has been shown that activated antigen-
specific T cells, B cells, and monocytes produce BDNF and
IL-6 [27–29]. Indeed, TNF-α represents a specific link between
monocyte infiltration and neuronal changes in inflammatory
diseases. Furthermore, TNF-α and IL-6 play an important role
in regulating BDNF secretion [27–29].
Several evidences suggest a significant increase in infec-
tious and autoimmune diseases in individuals with DS, inde-
pendent of gender, age, family history, and exposure to other
risk factors, suggesting an intrinsic alteration of the immune
system [30]. Since DS is known to be characterized by a proin-
flammatory profile and then by an increase in proinflamma-
tory cytokines, including TNF-α and IL-6, it is reasonable
to hypothesize a concomitant alteration in the circulating
levels of neurotrophins.
Oxidative stress is a phenomenon associated with an
imbalance between the production of free radicals and reac-
tive metabolites (e.g., superoxide and hydrogen peroxide)
and the antioxidant defenses. Oxidative stress has been asso-
ciated with the known various morphological abnormalities,
immune disorders, intellectual disability, premature aging,
and other biochemical abnormalities of DS individuals; fur-
thermore, the Cu/Zn superoxide dismutase (SOD) gene is
located on the 21st chromosome [31]. Indeed, many studies
examined the impact of antioxidant interventions as well as
the positive effect of physical exercise on cognitive and learn-
ing disabilities of individuals with DS proposing BDNF as a
potential therapeutic target at the molecular level [31–33].
Although crucial findings are available for adults with
DS, only a few data are existing on the correlation between
neuroinflammation and oxidative stress in prepubertal, the
period of life immediately before puberty, DS children. Thus,
the current study was designed to determine and correlate in
prepubertal male and female DS children (i) the serum levels
of NGF and BDNF; (ii) the oxidative status measured in the
serum as free oxygen radicals defense (FORD) and free oxy-
gen radicals test (FORT); and (iii) the serum levels of cyto-
kines playing subtle roles in both neuroinflammatory and
oxidative processes as TNF-α, transforming growth factor-
beta (TGF-β), Monocyte Chemoattractant Protein-1 (MCP-
1), IL-1α, IL-2, IL-6, IL-10, and IL-12.
2. Materials and Methods
2.1. Participants’ Selection. Patients enrolled in the present
study were 9 individuals with Down Syndrome in follow up
at the genetics ambulatory of the Department of Pediatrics
of the Sapienza University Hospital “Policlinico Umberto I”
of Rome, Italy. DS participants were 9 prepubertal children
(5 males and 4 females) aged between 1 and 9.6 years who
have been diagnosed for Down Syndrome with free trisomy
21 by both clinical and molecular analyses. The karyotype
analysis involved different steps: first, the culture of lympho-
cytes, then the chromosome banding, and in the end a micro-
scopic analysis [34]. For all patients, a peripheral venous
blood sample was collected and conserved in 3ml heparin
tube from which the lymphocytes were isolated and cultured
for 72 hours at 37°C [35, 36]. The chromosomal banding was
then carried out using the G-banding (Giemsa banding using
Trypsin) kit by Thermo Fisher (Waltham, MA, USA) per-
formed according to the manufacturer’s instructions [36].
For each patient blood sample, 100 metaphase cells with an
average resolution of 400 bands were recorded. For DS chil-
dren recruitment, several investigations were carried out:
(1) physiological anamnesis: type of delivery and gestational
age at the time of birth, type of breastfeeding, age of weaning,
eating habits, and age; (2) close and remote pathological
anamnesis; (3) pharmacological anamnesis; (4) family his-
tory: diseases, parents’ age at pregnancy, and parents’ edu-
cation; and (5) physical examination and anthropometric
parameters measurements: gender, ethnicity, weight, and
height. In DS prepubertal children, the peripheral venous
blood sample was collected for the karyotype analysis.
The control group consisted of 21 age-matched healthy
prepubertal children (10 males and 11 females) selected at
the Department of Pediatrics of the Sapienza University Hos-
pital “Policlinico Umberto I” of Rome, Italy. We have
selected these children because they were recovered in the
hospital for the investigation of the presumed pathologies
that resulted not present at all, defining thus the children
“healthy.” For both control children and DS individuals, the
peripheral venous blood sample was collected at the moment
of discharge for routine analyses.
2 Journal of Immunology Research
Main exclusion criteria for the enrollment in the study for
all children included (1) puberty in place or postpuberty; (2)
use of drugs or chemicals that can alter the serum levels of
inflammation markers, such as antidepressants, anti-inflam-
matory, and immunosuppressant; (3) inflammatory, endo-
crine, and autoimmune disorders such as thyroiditis and
celiac disease; (4) other ongoing pathologies; and (5) children
with diagnosed cardiovascular pathologies that could have
biased inflammatory analyses. We consider puberty as the
process of physical changes through which a child’s body
matures into an adult body capable of sexual reproduction.
We included the enrolled subjects in the prepubertal age
phase by Tanner scale examination by pediatricians with
expertise in sexual development. The study was approved
by the Sapienza University Hospital ethical committee; an
informed consent was signed by each parent of the children
and all the study procedures were in accordance with the
Helsinki Declaration of 1975, as revised in 1983, for human
experimentation.
2.2. NGF and BDNF Serum Level Evaluation. Peripheral
blood samples of 5ml were taken from each participant, col-
lected in heparinized tubes, and centrifuged at 3000 rpm for
15min to separate serum from plasma. The serum separated
from the blood was then stored at –80°C. NGF (Cat. No.
DY256) and BDNF (Cat. No. DY248) were measured using
a sandwich enzyme-linked-immunosorbent assay (ELISA)
kits (R&D Systems, Minneapolis, MN, USA), according to
the protocols provided by the manufacturer and also accord-
ing to methods previously described [37–39]. Serum samples
were diluted 2- and 100-fold with PBS for detection of NGF
and BDNF, respectively. The colorimetric reaction product
was measured at 450 nm using a microplate reader (Dyna-
tech MR 5000, PBI International, USA). Data are represented
as pg/mg total proteins and all assays were performed in
duplicate which was averaged for statistical comparison.
2.3. Free Oxygen Radicals Defense (FORD) and Free Oxygen
Radicals Test (FORT). FORD and FORT tests were carried
out using two specific kits (both purchased by Callegari,
Parma, Italy) following the instruction provided by the man-
ufacturer and according to methods previously described
[37–39]. Blood serum was used both for the FORT and
FORD determination. FORD test allows the determination
of free oxygen radicals defense. Briefly, this test uses a pre-
formed stable and colored radical and determines the
decrease in absorbance that is proportional to the antioxidant
concentration of the sample [40].
By contrast, the FORT test allows the determination of
free oxygen radicals (ROS) through a colorimetric assay
based on the ability of transition metals, such as iron, to cat-
alyze the breakdown of hydroperoxides (ROOH) into deriv-
ative radicals, according to Fenton’s reaction [40].
2.4. Oxidative Stress ELISA Strip Profiling Assay. Expression
patterns of cytokines were studied in the enrolled DS prepu-
bertal children and healthy control children by using Human
Oxidative Stress ELISA Strip for Profiling 8 Cytokines (Cata-
log Number EA-1301, purchased by Signosis) that simulta-
neously analyzes the following cytokines: TNF-α, TGF-β,
MCP-1, IL-1α, IL-2, IL-6, IL-10, and IL-12. Briefly, 100μl
of the sample was added per well and was incubated for 2
hours at room temperature with gentle shaking. Then, each
well was aspirated and washed, three times, by adding
200μl of 1X Assay wash buffer. After the last wash, 100μl
of the diluted biotin-labeled antibody mixture was added to
each well and incubated for 1 hour at room temperature, with
gentle shaking. Then, the aspiration/wash was repeated as
described above. 100μl of diluted streptavidin-HRP conju-
gate was added to each well and incubated for 45min at room
temperature with gentle shaking. The plate was washed again
and 100μl substrate was added to each well and incubated for
10-30minutes. 50μl of Stop solution was added to each well
observing a color change from blue to yellow. Then, the opti-
cal density of each well was determined with a microplate
reader at 450 nm within 30 minutes.
2.5. Statistical Analysis. Serum NGF, BDNF, FORT/FORD,
and cytokines in DS prepubertal children were analyzed
using two-way analysis of variance (ANOVA) (DS children
versus control children and gender effect). Post hoc compar-
isons were performed using Tukey’s HSD test.
3. Results
3.1. Characteristics of the Subjects Included in the Study.
Table 1 shows the anamnestic and anthropometric findings
of the children and their parents included in the study. No
differences between groups were revealed by statistical analy-
ses because data on age, weight, height, and BMI displayed
high variability between children.
3.2. NGF and BDNF Serum Levels. Figures 1 and 2 show the
serum levels of NGF and BDNF, respectively, in male and
female DS prepubertal children and in the control group
(Figures 1(a) and 2(a) show the data according to gender
but Figures 1(b) and 2(b) are without it). As for NGF
(Figures 1(a) and 1(b)), data show great variability within
the DS children group, which did not induce significant dif-
ferences between DS and control groups (p = 0:201). Quite
interestingly, a significant difference emerges in the BDNF
serum levels between DS and control groups in the ANOVA
for the Down Syndrome condition. Indeed, data indicate a
potentiation in serum BDNF values (p = 0:04; Figure 2(b); p
< 0:05 in the post hoc). Furthermore, no gender differences
were observed for serum BDNF (Figure 2(a)).
3.3. Oxidative Stress Evaluation. This study revealed no dif-
ferences between DS children, and controls were found in
FORD and FORT parameters, neither if analyzed for the gen-
der parameter (Figure 3, left panels for the full interaction
and the right panels without the gender effect).
3.4. Serum Levels of TNF-α, TGF-β, MCP-1, IL-1α, IL-2, IL-6,
IL-10, and IL-12. Figure 4 shows the ANOVA data graphical
expression of serum TNF-α, TGF-β, MCP-1, IL-1α, IL-2, IL-
6, IL-10, and IL-12 of male and female children affected by
Down Syndrome compared to healthy male and female chil-
dren used as controls.
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Table 1: Anamnestic and anthropometric data of the children or their parents included in the study. Data are expressed as means ± SE, as
median, or as percentage.
Down Healthy
Gender Male Female Male Female
Number 5 4 10 11
Age 6 ± 2:9 3:8 ± 5:6 7:13 ± 2:91 7:8 ± 3:4
Weight (kg) 20:7 ± 9:6 15:8 ± 16:7 27:19 ± 18:6 27:25 ± 13:04
Height (cm) 108:5 ± 23:1 86:3 ± 35:2 116:5 ± 27:5 126:5 ± 20:3
BMI 17:39 ± 0:75 19:01 ± 2:97 19:55 ± 2:61 16:12 ± 0:92
Feeding time (%)
Breast milk 20 0 45.4 40
Artificial milk 60 25 27.3 20
Mixed milk 20 75 273 40
Weaning (%)
Before 5 months 0 0 0 30
Between 5 and 6 months 60 75 100 30
Over 6 months 40 25 0 40
Birth (%)
Normal 60 50 100 60
Preterm (nonpathologic) 40 50 0 40
Mode of delivery
Vaginal 40 50 45.5 50
Caesarean 60 50 54.5 50
Age of parents to pregnancy
Mother 36:75 ± 3:3 32:67 ± 8:14 32:6 ± 7:2 32:44 ± 8:62
Father 44:75 ± 4:27 36:67 ± 3:79 35:9 ± 3:9 36:67 ± 8:47
Educational level of parents (%) Mother Father Mother Father Mother Father Mother Father
No education 0 0 0 0 0 0 0 0
Primary school 0 0 0 0 0 0 0 0
Secondary school of I degree 0 60 0 0 36.4 27.25 20.0 30.0
Secondary school of II degree 100 40 100 60 27.2 4.5 50.0 30.0
University degree 0 0 0 40 36.4 27.25 30.0 40.0
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Figure 1: Nerve growth factor (NGF) levels in male and female DS prepubertal children and in the control group ((a) shows the data
according to gender but (b) are without it). The error bars indicate pooled standard error means (SEM) derived from appropriate error
mean square in the ANOVA.
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ANOVA clearly evidences differential expression of
serum inflammatory cytokines between prepubertal DS chil-
dren and controls. Indeed, low expression in DS prepubertal
children, and in particular, in DS prepubertal female children
were observed for TNF-α, TGF-β, and MCP-1 (p < 0:05 in
the ANOVAs; p < 0:05 in post hoc between groups). Similar
findings, but with decreased expression in DS prepubertal
male children, were revealed for IL-6 and IL-12 (p < 0:01 in
the ANOVAs; p < 0:01 in post hoc between groups). As for
IL-1α, IL-2, and IL-10, data clearly disclose low serum
expression of these cytokines in DS prepubertal children
compared to controls with no differences due to gender
(p < 0:05 in the ANOVAs; p < 0:05 in post hoc between
groups).
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Figure 2: Brain-derived neurotrophic factor (BDNF) levels in male and female DS prepubertal children and in the control group ((a) shows
the data according to gender but (b) are without it). The error bars indicate pooled standard error means (SEM) derived from appropriate
error mean square in the ANOVA. The asterisk indicates significant differences between groups (∗p < 0:05).
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Figure 3: Free oxygen radicals test (FORT) and free oxygen radicals defense (FORD) levels in male and female DS prepubertal children and in
the control group (the left panels represent the full interaction and the right panels are without the gender effect). The error bars indicate
pooled standard error means (SEM) derived from appropriate error mean square in the ANOVA.
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4. Discussion
This is the first study investigating in prepubertal DS children
the relationship between neurotrophins, oxidative stress, and
neuroinflammatory markers in the serum. Indeed, we evi-
denced, although without NGF, FORD, and FORT changes,
BDNF elevation and a marked reduction of TNF-α, TGF-β,
MCP-1, IL-1α, IL-2, IL-6, IL-10, and IL-12. We also demon-
strated for the first time different gender responses between
males and females DS children in the analyzed cytokines.
As for oxidative stress in DS, we did not find changes in
prepubertal DS children in the parameters of oxidation we
investigated. However, some animal model and human stud-
ies have shown that the activity of the superoxide dismutase
enzyme (SOD) is elevated in Down Syndrome [41, 42].
SOD converts oxygen radicals into hydrogen peroxide and
water. Oxygen radicals produced in cells can be damaging
to cellular structures, hence the important role of SOD. How-
ever, it has been hypothesized that if SOD activity increases
disproportionately to enzymes responsible for the removal
of hydrogen peroxide (e.g., glutathione peroxidase), the cells
will suffer from peroxide damage. It has been speculated that
the treatment of Down Syndrome neurons with free radical
scavengers could prevent neuronal degeneration [31]. In fact,
oxidative damage to neurons could lead to rapid brain aging
similar to that of Alzheimer’s disease. Quite interestingly, the
DNA oxidation product 8-OHdG (8-Oxo-2′-deoxyguano-
sine (8-oxo-dG)) in adults with DS measured in saliva was
found to be significantly higher than in the control groups
[43]. 8-OHdG levels were also found to be higher in urine
0
200
400
600
800
TN
F𝛼
 (O
D
 4
50
⁎
10
00
)
0
200
400
600
800
TG
F𝛽
 (O
D
 4
50
⁎
10
00
)
0
200
400
600
M
CP
-1
 (O
D
 4
50
 ⁎
10
00
)
IL
-2
 (O
D
 4
50
 ⁎
10
00
)
IL
-1
0 
(O
D
 4
50
 ⁎
10
00
)
IL
-1
2 
(O
D
 4
50
 ⁎
10
00
)
IL
-6
 (O
D
 4
50
 ⁎
10
00
)
IL
-𝛼
 (O
D
 4
50
 ⁎
10
00
)
0
200
400
600
0
200
400
600
0
200
400
600
0
200
400
600
0
200
400
600
Healthy children DS children Healthy children DS children 
FemalesMalesFemalesMalesFemalesMalesFemalesMales
TNF-𝛼 TGF-𝛽
MCP-1 IL-1𝛼
IL-2 IL-6
IL-10 IL-12
⁎
⁎⁎
⁎
⁎⁎
⁎⁎
⁎⁎
⁎⁎
⁎⁎
⁎⁎
⁎⁎
⁎⁎
⁎
⁎⁎
Figure 4: TNF-α, TGF-β, MCP-1, IL-1α, IL-2, IL-6, IL-10, and IL-12 serum levels in male and female DS prepubertal children and in the
control group. The error bars indicate pooled standard error means (SEM) derived from appropriate error mean square in the ANOVA.
The asterisks indicate significant differences between groups (∗p < 0:05); (∗∗p < 0:01).
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[44] and leukocytes [45] of persons with DS compared to
controls. These findings suggest that oxidative DNA dam-
age may underlie some of the clinical and premature aging
features of DS.
For what concerns neurotrophins in DS, it has been pre-
viously shown that serum changes in the levels of both NGF
and BDNF [46–48]. In the present study, we found BDNF
elevation suggesting that high levels of circulating BDNF
could protect DS patients from the clinical complications of
atherosclerosis [46]. However, the striking drop in peripheral
BDNF levels with age might predispose these patients to clin-
ical manifestations of dementia in later life [46]. Quite inter-
estingly, as previously reported [46], DS is considered a
condition with a low risk of clinical atherosclerosis and car-
diovascular disease during adult and later life. A potentiation
of biomolecules with functional activities in endothelial cell
activation [49, 50] should promote the risk of atherosclerosis
in DS. However, since DS is considered an atheroma-free
model [51] and clinical studies do not report any increase
in the risk of cardiovascular disease in adult and elderly
patients, DS individuals constitute a still unsolved biologi-
cal/clinical paradox [47]. Among our cohort of DS prepuber-
tal children, we did not disclose differences in NGF levels.
However, a previous study did not reveal differences in serum
NGF between prepubertal DS children and controls [48]
while potentiation in NGF serum levels of DS children was
reported in another investigation [47] demonstrating that
the age parameter in DS children could be a confounding
factor. Disrupted serum BDNF may correlate also with the
elevated risk of dementia in DS individuals. Indeed, Alzhei-
mer’s disease is most likely universal in older individuals
with Down Syndrome due to having three copies of the amy-
loid precursor protein gene, resulting in amyloid-beta plaque
deposition [52, 53]. Older adults with Down Syndrome often
present with cognitive decline: more than 80% may experi-
ence dementia by age 65 years. However, further investiga-
tion is required to better understand and disclose the
biomarkers of the disorder progression and their relation-
ship with symptom development during the presymptom-
atic period [52, 53].
DS individuals typically have a poor immune function
and generally reach developmental milestones at a later age.
They have an increased risk of a number of other health
problems, including congenital heart defects, epilepsy, leuke-
mia, thyroid and autoimmune diseases, and mental disor-
ders. Indeed, DS persons may have a high frequency of
infections, usually of the upper respiratory tract, character-
ized by increased severity and prolonged course of the dis-
ease, which are partially attributed to defects of the immune
system. The abnormalities of the immune system associated
with DS include mild to moderate T and B cell lymphopenia,
with a marked decrease in naive lymphocytes, impaired
mitogen-induced T cell proliferation, reduced specific anti-
body responses to immunizations, and defects of neutrophil
chemotaxis. Limited evidence of genetic abnormalities sec-
ondary to trisomy of chromosome 21 and affecting the
immune system is available, such as the potential conse-
quences of gene overexpression [30]. Secondary immunode-
ficiency due to metabolic or nutritional factors in DS,
particularly calcium, selenium, and zinc deficiency, has been
also postulated [54]. However, the molecular mechanisms
leading to the immune defects observed in DS individuals
and the contribution of these immunological abnormalities
remain largely unknown, especially in DS prepubertal chil-
dren [55]. Children with Down Syndrome develop more
infections, have an increased mortality from sepsis, and an
increased incidence of chronic inflammatory conditions
[56]. Cytokine dysregulation may underpin these clinical
sequelae and raised proinflammatory biomarkers are a fea-
ture in adults with DS [56]. Changes in young and adult DS
individuals’ immune response is modulated by the levels of
pro- and anti-inflammatory cytokines [57, 58] depending
on many factors as the severity and extension of the trisomy
21, the presence of concomitant immunological disorders,
infections, age, oxidative stress, congenital heart diseases,
neurological impairments, and blood/nonblood cancers [59,
60]. In the sample of the present study of prepubertal DS
children characterized by restricted recruitment criteria as
no use of drugs or chemicals, concomitant inflammatory,
endocrine and autoimmune disorders, or diagnosed cardio-
vascular pathologies, we found a significant decrease in the
serum levels of TNF-α, TGF-β, MCP-1, IL-1α, IL-2, IL-6,
IL-10, and IL-12. In addition, we disclosed for the first time
different gender responses between males and females DS
children in the analyzed serum cytokines. We do hypothesize
that the low levels of the analyzed cytokines in the serum of
DS prepubertal children could be due to a physiological delay
and/or disrupted normal development of the individuals’
immune system as previously reported for both DS subjects
and DS animal models [61–63] with different cytokines pres-
ence between males and females prepubertal DS children. As
for gender differences in DS children, available data show
disparities between DS boys and girls mainly in major con-
genital heart defects [64, 65] and, as recently demonstrated,
in emotional and behavioral problems associated with
attention-deficit and hyperactivity disorders [66]. These data
could be associated with the differences in serum cytokines
analyzed in our study.
A further element of discussion, also related to the
BDNF changes we found, is the relationship between these
alterations in neuroinflammatory markers and the devel-
opment of dementia in DS individuals. Actually, the spe-
cific chromosome 21 gene products and the complexity
of the mechanisms they engender that give rise to the neu-
roinflammatory responses noted in fetal development of the
DS brain and their potential as accelerators of Alzheimer
neuropathogenesis in DS are crucial topics, particularly as
they relate to the development and propagation of neuroin-
flammation, the consequences of which are recognized clini-
cally and neuropathologically as dementia-like diseases [67].
We do believe that the strength of this study is that both
controls and DS individuals underwent the same stressing
conditions since they both came from the pediatrics section
of a university hospital with similar blood collection rules
and according to restricted subject recruitments’ procedures
(see methods, in particular for control individuals’ enroll-
ment). Furthermore, according to the exclusion criteria for
the DS individuals’ enrollment in the study, based on the
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university hospital standard analyses, we did not include
children with anomalies in insulin-like growth factors
(IGF-1) and thyroid hormones, quite common in DS chil-
dren that could have biased the results on the neuroinflam-
matory markers. Of course, a limit of the study is the
relatively low number of individuals enrolled in the experi-
mentation but that depends on its strength (restricted enroll-
ment rules). Since DS individuals display high variability in
learning and memory abilities, another, but secondary, limit
of the study is the lack of neurocognitive analyses to study
changes in neurodevelopment and to correlate these findings
also with the neuroinflammatory markers.
A future direction of this investigation by increasing the
number of the enrolled subjects is the possibility to follow-
up the patients over time to check whether or not early
changes in neuroinflammatory markers could be associated
with a premature onset of dementia-like diseases to early
establish more efficacious treatment protocols.
The present investigation may represent a step forward in
the attempt to unravel some biomolecular processes and
responses underlying the DS immune system development
and functionality. These results may be of interest also for
studies in the fields of human genetic disorders in children.
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